Tryptophan, Neurodegeneration and HIV-Associated Neurocognitive Disorder

This review presents an up-to-date assessment of the role of the tryptophan metabolic and catabolic pathways in neurodegenerative disease and HIV-associated neurocognitive disorder. The kynurenine pathway and the effects of each of its enzymes and products are reviewed. The differential expression of the kynurenine pathway in cells within the brain, including inflammatory cells, is explored given the increasing recognition of the importance of inflammation in neurodegenerative disease. An overview of common mechanisms of neurodegeneration is presented before a review and discussion of the evidence for a pathogenetic role of the kynurenine pathway in Alzheimer's disease, HIV-associated neurocognitive disorder, Huntington's disease, motor neurone disease, and Parkinson's disease.

[1]  M. Beal,et al.  Mitochondrial Dysfunction in Neurodegenerative Diseases , 2012, Journal of Pharmacology and Experimental Therapeutics.

[2]  V. Meininger,et al.  The Kynurenine Pathway and Inflammation in Amyotrophic Lateral Sclerosis , 2010, Neurotoxicity Research.

[3]  Brent D. Cameron,et al.  Inflammation, microglia, and alzheimer's disease , 2010, Neurobiology of Disease.

[4]  Victor Tapias,et al.  Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model , 2010, Journal of neuroscience research.

[5]  B. Brew,et al.  Effect of quinolinic acid on human astrocytes morphology and functions: implications in Alzheimer's disease , 2009, Journal of Neuroinflammation.

[6]  Gilles J. Guillemin,et al.  The Excitotoxin Quinolinic Acid Induces Tau Phosphorylation in Human Neurons , 2009, PloS one.

[7]  P. Klivényi,et al.  Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies , 2009, Journal of Neural Transmission.

[8]  Gregory J. Hardy,et al.  Kynurenic Acid Triggers Firm Arrest of Leukocytes to Vascular Endothelium under Flow Conditions* , 2009, The Journal of Biological Chemistry.

[9]  B. Brew,et al.  Mechanism for Quinolinic Acid Cytotoxicity in Human Astrocytes and Neurons , 2009, Neurotoxicity Research.

[10]  E. Hirsch,et al.  Neuroinflammation in Parkinson's disease: a target for neuroprotection? , 2009, The Lancet Neurology.

[11]  G. Smythe,et al.  Age and circadian influences on picolinic acid concentrations in human cerebrospinal fluid , 2009, Journal of neurochemistry.

[12]  E. Hirsch,et al.  Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. , 2008, The Journal of clinical investigation.

[13]  C. Gragnoli,et al.  What do we know about serotonin? , 2008, Journal of cellular physiology.

[14]  W. Kiosses,et al.  Decreased neuronal autophagy in HIV dementia: A mechanism of indirect neurotoxicity , 2008, Autophagy.

[15]  F. V. van Bockxmeer,et al.  The relationship between ApoE, TNFA, IL1a, IL1b and IL12b genes and HIV‐1‐associated dementia , 2008, HIV medicine.

[16]  R. Reiter,et al.  Biogenic amines in the reduction of oxidative stress: melatonin and its metabolites. , 2008, Neuro endocrinology letters.

[17]  G. Kemmler,et al.  Quality of life and immune activation in patients with HIV-infection , 2008, Brain, Behavior, and Immunity.

[18]  Venkataramanujam Srinivasan,et al.  Immunomodulation by Melatonin: Its Significance for Seasonally Occurring Diseases , 2008, Neuroimmunomodulation.

[19]  H. Lee,et al.  Kynurenic acid attenuates MPP(+)-induced dopaminergic neuronal cell death via a Bax-mediated mitochondrial pathway. , 2008, European journal of cell biology.

[20]  K. Strebel,et al.  HIV-1 Vif, APOBEC, and Intrinsic Immunity , 2008, Retrovirology.

[21]  Robert A. Smith,et al.  Resistance to kynurenic acid of the NMDA receptor-dependent toxicity of 3-nitropropionic acid and cyanide in cerebellar granule neurons , 2008, Brain Research.

[22]  Rebekah L. Gundry,et al.  Nitrosative stress with HIV dementia causes decreased L-prostaglandin D synthase activity , 2008, Neurology.

[23]  D. Aunis,et al.  Xanthurenic acid distribution, transport, accumulation and release in the rat brain , 2008, Journal of neurochemistry.

[24]  B. Brew,et al.  Kynurenine pathway metabolism in human blood–brain–barrier cells: implications for immune tolerance & neurotoxicity , 2008, Journal of neurochemistry.

[25]  J. McArthur,et al.  Converging roles for sphingolipids and cell stress in the progression of neuro-AIDS. , 2008, Frontiers in bioscience : a journal and virtual library.

[26]  R. Schwarcz,et al.  Histone Deacetylase Inhibition Modulates Kynurenine Pathway Activation in Yeast, Microglia, and Mice Expressing a Mutant Huntingtin Fragment* , 2008, Journal of Biological Chemistry.

[27]  H. Rammensee,et al.  Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. , 2008, Blood.

[28]  A. Venkatesan,et al.  Evolution of HIV dementia with HIV infection , 2008, International review of psychiatry.

[29]  B. Brew,et al.  The involvement of astrocytes and kynurenine pathway in Alzheimer’s disease , 2007, Neurotoxicity Research.

[30]  Gilles J Guillemin,et al.  Characterization of the Kynurenine Pathway in Human Neurons , 2007, The Journal of Neuroscience.

[31]  M. J. Leon,et al.  Longitudinal CSF isoprostane and MRI atrophy in the progression to AD , 2007, Journal of Neurology.

[32]  B. Brew,et al.  Mass spectrometric detection of quinolinic acid in microdissected Alzheimer's disease plaques , 2007 .

[33]  J. Becker,et al.  Updated research nosology for HIV-associated neurocognitive disorders , 2007, Neurology.

[34]  W. Markesbery,et al.  Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease , 2007, Nucleic acids research.

[35]  Holger Heine,et al.  Role of the Toll-Like Receptor 4 in Neuroinflammation in Alzheimer’s Disease , 2007, Cellular Physiology and Biochemistry.

[36]  L. Looger,et al.  Nanosensor Detection of an Immunoregulatory Tryptophan Influx/Kynurenine Efflux Cycle , 2007, PLoS biology.

[37]  T. Stone,et al.  Tryptophan, adenosine, neurodegeneration and neuroprotection , 2007, Metabolic Brain Disease.

[38]  Gwang Lee,et al.  Neuroprotective effect of nicotine on dopaminergic neurons by anti‐inflammatory action , 2007, The European journal of neuroscience.

[39]  R. Schwarcz,et al.  Mitochondrial aspartate aminotransferase: a third kynurenate‐producing enzyme in the mammalian brain , 2007, Journal of neurochemistry.

[40]  L. Jermiin,et al.  Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. , 2007, Gene.

[41]  J. Toldi,et al.  Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders , 2007, Journal of the Neurological Sciences.

[42]  J. Kaye,et al.  Blood–brain barrier impairment in Alzheimer disease , 2007, Neurology.

[43]  H. Tomioka,et al.  Effects of picolinic acid on the antimicrobial functions of host macrophages against Mycobacterium avium complex. , 2007, International journal of antimicrobial agents.

[44]  F. Cimadamore,et al.  Tissue expression and biochemical characterization of human 2‐amino 3‐carboxymuconate 6‐semialdehyde decarboxylase, a key enzyme in tryptophan catabolism , 2007, The FEBS journal.

[45]  M. Wajner,et al.  Kynurenines Impair Energy Metabolism in Rat Cerebral Cortex , 2007, Cellular and Molecular Neurobiology.

[46]  J. E. Kudlow,et al.  Induction of Macrophage Glutamine: Fructose-6-Phosphate Amidotransferase Expression by Hypoxia and by Picolinic Acid , 2007, International journal of immunopathology and pharmacology.

[47]  Yuan Wang,et al.  Synovial Autoreactive T Cells in Rheumatoid Arthritis Resist IDO-Mediated Inhibition1 , 2006, The Journal of Immunology.

[48]  Tony Wyss-Coray,et al.  Inflammation in Alzheimer disease: driving force, bystander or beneficial response? , 2006, Nature Medicine.

[49]  D. Nutt,et al.  Tryptophan metabolism in the central nervous system: medical implications , 2006, Expert Reviews in Molecular Medicine.

[50]  M. MacDonald,et al.  Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice , 2006, Neurobiology of Disease.

[51]  L. Vécsei,et al.  Effect of 6-hydroxydopamine treatment on kynurenine aminotransferase-I (KAT-I) immunoreactivity of neurons and glial cells in the rat substantia nigra , 2006, Acta Neuropathologica.

[52]  D J Brooks,et al.  Microglial activation correlates with severity in Huntington disease , 2006, Neurology.

[53]  M. Fernstrom,et al.  Exercise, serum free tryptophan, and central fatigue. , 2006, The Journal of nutrition.

[54]  R. Rosenthal,et al.  Differential effects of the tryptophan metabolite3‐hydroxyanthranilic acid on the proliferation of human CD8+ T cells induced by TCR triggering or homeostatic cytokines , 2006, European journal of immunology.

[55]  R. Schwarcz,et al.  Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease , 2006, Experimental Neurology.

[56]  R. Hider,et al.  The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy , 2005, British journal of pharmacology.

[57]  T. Chase,et al.  Susceptibility of striatal neurons to excitotoxic injury correlates with basal levels of Bcl-2 and the induction of P53 and c-Myc immunoreactivity , 2005, Neurobiology of Disease.

[58]  Alexander Gerhard,et al.  Microglial activation in presymptomatic Huntington's disease gene carriers. , 2005, Brain : a journal of neurology.

[59]  B. Brew,et al.  Indoleamine 2,3 dioxygenase and quinolinic acid Immunoreactivity in Alzheimer's disease hippocampus , 2005, Neuropathology and applied neurobiology.

[60]  W. Turski,et al.  Demonstration of Kynurenine Aminotransferases I and II and Characterization of Kynurenic Acid Synthesis in Oligodendrocyte Cell Line (OLN-93) , 2005, Neurochemical Research.

[61]  B. Brew,et al.  Quinolinic acid selectively induces apoptosis of human astrocytes: potential role in AIDS dementia complex , 2005, Journal of Neuroinflammation.

[62]  P. Shaw,et al.  Molecular and cellular pathways of neurodegeneration in motor neurone disease , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[63]  W. Turski,et al.  Demonstration of kynurenine aminotransferases I and II and characterization of kynurenic acid synthesis in cultured cerebral cortical neurons , 2005, Journal of neuroscience research.

[64]  T. Stone,et al.  Tryptophan metabolism and oxidative stress in patients with Huntington's disease , 2005, Journal of neurochemistry.

[65]  J. Toldi,et al.  Systemically administered glucosamine-kynurenic acid, but not pure kynurenic acid, is effective in decreasing the evoked activity in area CA1 of the rat hippocampus. , 2005, European journal of pharmacology.

[66]  T. Stone.  Adenosine, neurodegeneration and neuroprotection , 2005, Neurological research.

[67]  A. Boasso,et al.  Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells. , 2005, Blood.

[68]  G. Prendergast,et al.  Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy , 2005, Nature Medicine.

[69]  B. Csillik,et al.  Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment , 2004, Neuroscience.

[70]  D. Munn,et al.  Ido expression by dendritic cells: tolerance and tryptophan catabolism , 2004, Nature Reviews Immunology.

[71]  N. Nukina,et al.  Increased expression of p62 in expanded polyglutamine‐expressing cells and its association with polyglutamine inclusions , 2004, Journal of neurochemistry.

[72]  R. Bendayan,et al.  Functional Expression and Localization of P-glycoprotein in the Central Nervous System: Relevance to the Pathogenesis and Treatment of Neurological Disorders , 2004, Pharmaceutical Research.

[73]  P. Doraiswamy,et al.  Metals in our minds: therapeutic implications for neurodegenerative disorders , 2004, The Lancet Neurology.

[74]  V. Felipo,et al.  Acute ammonia intoxication induces an NMDA receptor‐mediated increase in poly(ADP‐ribose) polymerase level and NAD+ metabolism in nuclei of rat brain cells , 2004, Journal of neurochemistry.

[75]  A. Ghorpade,et al.  Alcohol and HIV decrease proteasome and immunoproteasome function in macrophages: implications for impaired immune function during disease. , 2004, Cellular immunology.

[76]  R. Price,et al.  CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy. , 2004, Brain : a journal of neurology.

[77]  R. Rissman,et al.  Biochemical and molecular studies of NMDA receptor subunits NR1/2A/2B in hippocampal subregions throughout progression of Alzheimer's disease pathology , 2004, Neurobiology of Disease.

[78]  B. Brew,et al.  A&bgr;1-42 induces production of quinolinic acid by human macrophages and microglia , 2003, Neuroreport.

[79]  R. Hawkins,et al.  Na+-dependent transport of large neutral amino acids occurs at the abluminal membrane of the blood-brain barrier. , 2003, American journal of physiology. Endocrinology and metabolism.

[80]  J. Papp,et al.  Effect of Systemic Administration of L‐Kynurenine on Corticocerebral Blood Flow under Normal and Ischemic Conditions of the Brain in Conscious Rabbits , 2003, Journal of cardiovascular pharmacology.

[81]  B. Baban,et al.  Cutting Edge: Induced Indoleamine 2,3 Dioxygenase Expression in Dendritic Cell Subsets Suppresses T Cell Clonal Expansion1 , 2003, The Journal of Immunology.

[82]  J. Moffett,et al.  Tryptophan and the immune response , 2003, Immunology and cell biology.

[83]  J. Berman,et al.  MCP‐1 (CCL2) protects human neurons and astrocytes from NMDA or HIV‐tat‐induced apoptosis , 2003, Journal of neurochemistry.

[84]  W. Turski,et al.  Endogenous protectant kynurenic acid in amyotrophic lateral sclerosis , 2003, Acta neurologica Scandinavica.

[85]  D. Rubinsztein,et al.  Transcriptional abnormalities in Huntington disease. , 2003, Trends in genetics : TIG.

[86]  R. Reiter,et al.  Melatonin, xanthurenic acid, resveratrol, EGCG, vitamin C and α‐lipoic acid differentially reduce oxidative DNA damage induced by Fenton reagents: a study of their individual and synergistic actions , 2003, Journal of pineal research.

[87]  L. Lima,et al.  Characterization of tryptophan high affinity transport system in pinealocytes of the rat. Day-night modulation , 2003, Amino Acids.

[88]  J. O'Brien,et al.  Effects of acute tryptophan depletion on cognitive function in Alzheimer's disease and in the healthy elderly , 2002, Psychological Medicine.

[89]  Y. Egashira,et al.  Identification and expression of alpha cDNA encoding human 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase (ACMSD): a key enzyme for the tryptophan-niacine pathway and quinolinate hypothesis. , 2002, Advances in experimental medicine and biology.

[90]  W. Turski,et al.  1-Methyl-4-phenylpyridinium and 3-nitropropionic acid diminish cortical synthesis of kynurenic acid via interference with kynurenine aminotransferases in rats , 2002, Neuroscience Letters.

[91]  B. Brew,et al.  Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease , 2002, Redox report : communications in free radical research.

[92]  T. Stone,et al.  Endogenous kynurenines as targets for drug discovery and development , 2002, Nature Reviews Drug Discovery.

[93]  D. Souza,et al.  Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes , 2002, Neurochemistry International.

[94]  R. Schwarcz,et al.  Effect of systemic L-DOPA administration on extracellular kynurenate levels in the rat striatum , 2002, Journal of Neural Transmission.

[95]  P. Hamilton,et al.  Antiviral, cytotoxic and apoptotic activities of picolinic acid on human immunodeficiency virus-1 and human herpes simplex virus-2 infected cells. , 2001, Anticancer research.

[96]  T. Dawson,et al.  The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders , 2001, Trends in Neurosciences.

[97]  R. Schwarcz,et al.  The Brain Metabolite Kynurenic Acid Inhibits α7 Nicotinic Receptor Activity and Increases Non-α7 Nicotinic Receptor Expression: Physiopathological Implications , 2001, The Journal of Neuroscience.

[98]  B. Brew,et al.  Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection , 2001, Journal of neurochemistry.

[99]  Barry Halliwell,et al.  Failure of the ubiquitin–proteasome system in Parkinson's disease , 2001, Nature Reviews Neuroscience.

[100]  O. Hess,et al.  Pathological apoptosis by xanthurenic acid, a tryptophan metabolite: activation of cell caspases but not cytoskeleton breakdown , 2001, BMC Physiology.

[101]  Victoria Arango,et al.  The Neurobiology and Genetics of Suicide and Attempted Suicide: A Focus on the Serotonergic System , 2001, Neuropsychopharmacology.

[102]  W. Cammer.  Oligodendrocyte killing by quinolinic acid in vitro , 2001, Brain Research.

[103]  A. Santamaría,et al.  Quinolinic acid induces oxidative stress in rat brain synaptosomes , 2001, Neuroreport.

[104]  Peter B. Reiner,et al.  β‐Amyloid efflux mediated by p‐glycoprotein , 2001 .

[105]  R. Pomerantz,et al.  Human Immunodeficiency Virus Type 1 Vpr Induces Apoptosis in Human Neuronal Cells , 2000, Journal of Virology.

[106]  L. Grimaldi,et al.  The pervasiveness of interleukin-1 in Alzheimer pathogenesis: a role for specific polymorphisms in disease risk , 2000, Experimental Gerontology.

[107]  D. Butterfield,et al.  Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. , 2000, Journal of structural biology.

[108]  Hassan Mohammad Naif,et al.  Induction of Indolamine 2,3-Dioxygenase in Primary Human Macrophages by Human Immunodeficiency Virus Type 1 Is Strain Dependent , 2000, Journal of Virology.

[109]  J. Pedraza-Chaverri,et al.  Effect of quinolinic acid on endogenous antioxidants in rat corpus striatum , 2000, Brain Research.

[110]  L. Vécsei,et al.  Effects of in vivo sodium azide administration on the immunohistochemical localization of kynurenine aminotransferase in the rat brain , 1999, Neuroscience.

[111]  C. Masters,et al.  Aqueous Dissolution of Alzheimer’s Disease Aβ Amyloid Deposits by Biometal Depletion* , 1999, The Journal of Biological Chemistry.

[112]  J. Kaldor,et al.  Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. , 1999, AIDS.

[113]  S. Fulle,et al.  Rapid desensitization of PC12 cells stimulated with high concentrations of extracellular S100 , 1999, Neuroscience.

[114]  J M Land,et al.  Nitric oxide, mitochondria and neurological disease. , 1999, Biochimica et biophysica acta.

[115]  T. Chase,et al.  Free radical scavenger OPC-14117 attenuates quinolinic acid-induced NF-kappaB activation and apoptosis in rat striatum. , 1999, Brain Research. Molecular Brain Research.

[116]  P. Gøtzsche,et al.  The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis. , 1998, Pharmacogenetics.

[117]  H. Tse,et al.  [3H]Homoquinolinate Binds to a Subpopulation of NMDA Receptors and to a Novel Binding Site , 1998, Journal of neurochemistry.

[118]  I. Lucki,et al.  The spectrum of behaviors influenced by serotonin , 1998, Biological Psychiatry.

[119]  S. Daya,et al.  Melatonin plays a protective role in quinolinic acid-induced neurotoxicity in the rat hippocampus , 1998, Journal of Chemical Neuroanatomy.

[120]  M. Gompels,et al.  Serum kynurenine-to-tryptophan ratio increases with progressive disease in HIV-infected patients. , 1998, Clinical chemistry.

[121]  B. Brew,et al.  Chronic exposure of human neurons to quinolinic acid results in neuronal changes consistent with AIDS dementia complex , 1998, AIDS.

[122]  N. Nishiyama,et al.  3‐Hydroxykynurenine, an Endogenous Oxidative Stress Generator, Causes Neuronal Cell Death with Apoptotic Features and Region Selectivity , 1998, Journal of neurochemistry.

[123]  C. Parsons,et al.  Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization. , 1997, The Journal of pharmacology and experimental therapeutics.

[124]  V. Kapoor,et al.  Immuno‐localization of kynurenine aminotransferase (KAT) in the rat medulla and spinal cord , 1997, Neuroreport.

[125]  S. Hochman,et al.  Neuronal excitatory properties of human immunodeficiency virus type 1 tat protein , 1997, Neuroscience.

[126]  J. Tenu,et al.  Inhibition of nitric oxide synthase expression and activity in macrophages by 3-hydroxyanthranilic acid, a tryptophan metabolite. , 1997, Archives of biochemistry and biophysics.

[127]  P. Brundin,et al.  Effects of α-phenyl-tert-butyl nitrone on neuronal survival and motor function following intrastriatal injections of quinolinate or 3-nitropropionate , 1996, Neuroscience.

[128]  H. Saito,et al.  3-Hydroxykynurenine toxicity on the rat striatum in vivo. , 1996, Japanese journal of pharmacology.

[129]  N. Botting.  Chemistry and neurochemistry of the kynurenine pathway of tryptophan metabolism , 1996 .

[130]  J. Xuereb,et al.  The messenger RNAs for the N-methyl- d-aspartate receptor subunits show region-specific expression of different subunit composition in the human brain , 1996, Neuroscience.

[131]  J. Rossier,et al.  THE ENDOGENEOUS AGONIST QUINOLINIC ACID AND THE NON ENDOGENOUS HOMOQUINOLINIC ACID DISCRIMINATE BETWEEN NMDAR2 RECEPTOR SUBUNITS , 1996, Neurochemistry International.

[132]  P. Ricciardi-Castagnoli,et al.  Regulation of the Kynurenine Metabolic Pathway by Interferon‐γ in Murine Cloned Macrophages and Microglial Cells , 1996, Journal of neurochemistry.

[133]  P. McGuffin,et al.  Mechanism of Enhancement of Rat Brain Serotonin Synthesis by Acute Fluoxetine Administration , 1996, Journal of neurochemistry.

[134]  M. Rosenblum,et al.  AIDS dementia complex and HIV‐1 brain infection: Clinical‐virological correlations , 1995, Annals of neurology.

[135]  A. Pati,et al.  The pineal gland: structural and functional diversity. , 1995, Indian journal of experimental biology.

[136]  R. Schwarcz,et al.  Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases , 1995, Journal of the Neurological Sciences.

[137]  R. Brownstone,et al.  Human immunodeficiency virus type 1 tat activates non—N‐methyl‐D‐aspartate excitatory amino acid receptors and causes neurotoxicity , 1995, Annals of neurology.

[138]  S. Oikawa,et al.  Metal-mediated oxidative damage to cellular and isolated DNA by certain tryptophan metabolites. , 1995, Carcinogenesis.

[139]  H. Reichmann,et al.  Electron transport chain defects in Alzheimer's disease. , 1994, Neurology.

[140]  C. Filley,et al.  Electron transport chain defects in Alzheimer's disease brain , 1994, Neurology.

[141]  S. Fulle,et al.  The brain protein S-100ab induces apoptosis in PC12 cells , 1994, Neuroscience.

[142]  H. Moss,et al.  Quinolinic acid in the cerebrospinal fluid of children with symptomatic human immunodeficiency virus type 1 disease: relationships to clinical status and therapeutic response. , 1993, The Journal of infectious diseases.

[143]  S. U. Kim,et al.  Glutamate neurotoxicity in mesencephalic dopaminergic neurons in culture , 1993, Journal of neuroscience research.

[144]  F. Waldhauser,et al.  Clinical aspects of the melatonin action: impact of development, aging, and puberty, involvement of melatonin in psychiatric disease and importance of neuroimmunoendocrine interactions , 1993, Experientia.

[145]  C. Achim,et al.  Quantitation of human immunodeficiency virus, immune activation factors, and quinolinic acid in AIDS brains. , 1993, The Journal of clinical investigation.

[146]  D. Giulian,et al.  The envelope glycoprotein of human immunodeficiency virus type 1 stimulates release of neurotoxins from monocytes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[147]  E. Hirsch,et al.  Glutathione peroxidase, glial cells and Parkinson's disease , 1993, Neuroscience.

[148]  C. Marsden,et al.  Mitochondrial function in Parkinson's disease , 1992, Annals of neurology.

[149]  R. Hales,et al.  J Neuropsychiatry Clin Neurosci , 1992 .

[150]  M. Demitrack,et al.  Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. , 1992, Brain : a journal of neurology.

[151]  S. Lipton.  Requirement for macrophages in neuronal injury induced by HIV envelope protein gp120. , 1992, Neuroreport.

[152]  M. Beal,et al.  Kynurenine pathway abnormalities in Parkinson's disease , 1992, Neurology.

[153]  E. Masliah,et al.  Spectrum of human immunodeficiency virus–associated neocortical damage , 1992, Annals of neurology.

[154]  Margaret Der,et al.  Inter-relationships between quinolinic acid, neuroactive kynurenines, neopterin and β2-microglobulin in cerebrospinal fluid and serum of HIV-1-infected patients , 1992, Journal of Neuroimmunology.

[155]  R. Schwarcz,et al.  Localization of kynurenine aminotransferase immunoreactivity in the rat hippocampus , 1992, The Journal of comparative neurology.

[156]  J. Glass,et al.  Cytokine expression in the brain during the acquired immunodeficiency syndrome , 1992, Annals of neurology.

[157]  A. Santamaría,et al.  Quinolinic acid is a potent lipid peroxidant in rat brain homogenates , 1991, Neurochemical Research.

[158]  T. Stoppard,et al.  The effects of lofepramine and desmethylimipramine on tryptophan metabolism and disposition in the rat. , 1991, Biochemical pharmacology.

[159]  R. Schwarcz,et al.  Blood–Brain Barrier Transport of Kynurenines: Implications for Brain Synthesis and Metabolism , 1991, Journal of neurochemistry.

[160]  E. Masliah,et al.  Neocortical damage during HIV infection , 1991, Annals of neurology.

[161]  P. Lantos,et al.  Neuronal loss in the frontal cortex in HIV infection , 1991, The Lancet.

[162]  A. Badawy,et al.  Effects of acute paroxetine administration on tryptophan metabolism and disposition in the rat , 1991, British journal of pharmacology.

[163]  J. Sidtis,et al.  Quinolinic acid in cerebrospinal fluid and serum in HIV‐1 Infection: Relationship to clinical and neurological status , 1991, Annals of neurology.

[164]  D. Griffin,et al.  Neopterin and interferon‐gamma in serum and cerebrospinal fluid of patients with HIV‐associated neurologic disease , 1991, Neurology.

[165]  D. Giulian,et al.  Secretion of neurotoxins by mononuclear phagocytes infected with HIV-1 , 1990, Science.

[166]  T. Guilarte,et al.  The role of hydrogen peroxide in the in vitro cytotoxicity of 3-hydroxykynurenine , 1990, Neurochemical Research.

[167]  R. Beninger,et al.  Quinolinate-induced cortical cholinergic damage: modulation by tryptophan metabolites , 1990, Brain Research.

[168]  D. Wong,et al.  Serotonin Uptake and Serotonin Uptake Inhibition , 1990, Annals of the New York Academy of Sciences.

[169]  R. Price,et al.  Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection , 1990, Annals of neurology.

[170]  M. Beal,et al.  Kynurenine Pathway Measurements in Huntington's Disease Striatum: Evidence for Reduced Formation of Kynurenic Acid , 1990, Journal of neurochemistry.

[171]  D. Dickson,et al.  Cellular localization of an HIV-1 antigen in subacute AIDS encephalitis using an improved double-labeling immunohistochemical method. , 1990, The American journal of pathology.

[172]  D. Surmeier,et al.  Quinolinate and kainate neurotoxicity in neostriatal cultures is potentiated by co-culturing with neocortical neurons , 1990, Brain Research.

[173]  W. Pardridge,et al.  Transport of Tryptophan into Brain from the Circulating, Albumin‐Bound Pool in Rats and in Rabbits , 1990, Journal of neurochemistry.

[174]  G. Reynolds,et al.  INCREASED BRAIN 3-HYDROXYKYNURENINE IN HUNTINGTON'S DISEASE , 1989, The Lancet.

[175]  T. Guilarte,et al.  Cytotoxicity of 3-hydroxykynurenine in a neuronal hybrid cell line , 1989, Brain Research.

[176]  A. H. V. Schapira,et al.  MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.

[177]  R. Price,et al.  Cerebrospinal fluid ß2 microglobulin in patients infected with human immunodeficiency virus , 1989, Neurology.

[178]  G. Lynch,et al.  A Glycine Site Associated with N‐Methyl‐d‐Aspartic Acid Receptors: Characterization and Identification of a New Class of Antagonists , 1989, Journal of neurochemistry.

[179]  R. Schwarcz,et al.  Prolonged exposure to submicromolar concentrations of quinolinic acid causes excitotoxic damage in organotypic cultures of rat corticostriatal system , 1989, Neuroscience Letters.

[180]  E. Kida,et al.  Neurotoxic effect induced by quinolinic acid in dissociated cell culture of mouse hippocampus , 1989, Journal of neuroscience research.

[181]  R. Schwarcz,et al.  Cerebrospinal fluid levels of quinolinic acid in Huntington's disease and schizophrenia , 1988, Annals of neurology.

[182]  C. Grossman,et al.  Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. , 1988, European journal of pharmacology.

[183]  P. Mcgeer,et al.  Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.

[184]  G. Reynolds,et al.  Brain Quinolinic Acid in Huntington's Disease , 1988, Journal of neurochemistry.

[185]  D. Choi,et al.  Quinolinate neurotoxicity in cortical cell culture , 1987, Neuroscience.

[186]  S. Rapoport,et al.  Kinetics of Neutral Amino Acid Transport Across the Blood‐Brain Barrier , 1987, Journal of neurochemistry.

[187]  Joseph B. Martin,et al.  Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid , 1986, Nature.

[188]  A. Patel,et al.  Immobilization Decreases Amino Acid Concentrations in Plasma but Maintains or Increases Them in Brain , 1986, Journal of neurochemistry.

[189]  S. Mazzari,et al.  Experimental models of aging and quinolinic acid. , 1985, Methods and findings in experimental and clinical pharmacology.

[190]  T. Stone,et al.  Actions of kynurenic acid and quinolinic acid in the rat hippocampus in vivo , 1985, Experimental Neurology.

[191]  H. Christensen,et al.  Organic ion transport during seven decades. The amino acids. , 1984, Biochimica et biophysica acta.

[192]  R. Schwarcz,et al.  Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid , 1984, Neuroscience Letters.

[193]  R. Schwarcz,et al.  Differential vulnerability of central neurons of the rat to quinolinic acid , 1983, Neuroscience Letters.

[194]  C. Giménez,et al.  Tryptophan Transport into Plasma Membrane Vesicles Derived from Rat Brain Synaptosomes , 1983, Journal of neurochemistry.

[195]  R. Schwarcz,et al.  Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. , 1983, Science.

[196]  A. Badawy,et al.  INHIBITION OF RAT LIVER TRYPTOPHAN PYRROLASE ACTIVITY AND ELEVATION OF BRAIN TRYPTOPHAN CONCENTRATION BY ACUTE ADMINISTRATION OF SMALL DOSES OF ANTIDEPRESSANTS , 1982, British journal of pharmacology.

[197]  M. Costa,et al.  Neurons with 5-hydroxytryptamine-like immunoreactivity in the enteric nervous system: Their projections in the guinea-pig small intestine , 1982, Neuroscience.

[198]  A. Sherman,et al.  l-Kynurenine Its synthesis and possible regulatory function in brain , 1980, Neurochemical Research.

[199]  N. Mizuno,et al.  Indoleamine 2,3-dioxygenase. Formation of L-kynurenine from L-tryptophan in cultured rabbit fineal gland. , 1978, The Journal of biological chemistry.

[200]  H. Baker,et al.  Positive identification of kynurenine in rat and human brain [proceedings]. , 1978, Biochemical Society transactions.

[201]  A. Mandell,et al.  Narcotic Drugs: Effects on the Serotonin Biosynthetic Systems of the Brain , 1972, Science.

[202]  B. Brew,et al.  Quinolinic acid is produced by macrophages stimulated by platelet activating factor, Nef and Tat , 2011, Journal of NeuroVirology.

[203]  B. Gelman,et al.  Brain aging in acquired immunodeficiency syndrome: Increased ubiquitin-protein conjugate is correlated with decreased synaptic protein but not amyloid plaque accumulation , 2011, Journal of NeuroVirology.

[204]  B. Brew,et al.  Involvement of quinolinic acid in aids dementia complex , 2009, Neurotoxicity Research.

[205]  A. Batra,et al.  Altered lymphocyte distribution in Alzheimer's disease. , 2007, Journal of psychiatric research.

[206]  M. Karásek,et al.  Melatonin in humans. , 2006, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[207]  A. Cesura,et al.  Expression of the kynurenine enzymes in macrophages and microglial cells: regulation by immune modulators , 2005, Amino Acids.

[208]  B. Brew,et al.  Expression of indoleamine 2,3‐dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons , 2005, Glia.

[209]  C. Sen,et al.  Mitochondrial nitric oxide synthase. , 2007, Frontiers in bioscience : a journal and virtual library.

[210]  P. Sanberg,et al.  Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. , 2004, Journal of neurochemistry.

[211]  D. Munn,et al.  IDO and tolerance to tumors. , 2004, Trends in molecular medicine.

[212]  S. Bano,et al.  Inhibition of tryptophan - pyrrolase activity and elevation of brain tryptophan concentration by fluoxetine in rats. , 2003, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.

[213]  R. Schwarcz,et al.  Kynurenate production by cultured human astrocytes , 2003, Journal of Neural Transmission.

[214]  B. Brew,et al.  Expression of the kynurenine pathway enzymes in human microglia and macrophages. , 2003, Advances in experimental medicine and biology.

[215]  R. Schwarcz,et al.  3-Hydroxykynurenine and quinolinate: pathogenic synergism in early grade Huntington's disease? , 2003, Advances in experimental medicine and biology.

[216]  Y. Egashira,et al.  Identification and expression of a cDNA encoding human alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase (ACMSD). A key enzyme for the tryptophan-niacine pathway and "quinolinate hypothesis". , 2002, The Journal of biological chemistry.

[217]  Kurt Zatloukal,et al.  p62 Is a common component of cytoplasmic inclusions in protein aggregation diseases. , 2002, The American journal of pathology.

[218]  R. Schwarcz,et al.  The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[219]  P. Reiner,et al.  beta-Amyloid efflux mediated by p-glycoprotein. , 2001, Journal of neurochemistry.

[220]  R. Reiter,et al.  An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease , 2000, Journal of Neural Transmission.

[221]  H. Budka,et al.  Kynurenic acid metabolism in the brain of HIV-1 infected patients , 2000, Journal of Neural Transmission.

[222]  D. Fuchs,et al.  Tryptophan degradation and immune activation in Alzheimer's disease , 2000, Journal of Neural Transmission.

[223]  K. Jellinger,et al.  Kynurenine metabolism in Alzheimer's disease , 1999, Journal of Neural Transmission.

[224]  D. Fuchs,et al.  Degradation of tryptophan in neurodegenerative disorders. , 1999, Advances in experimental medicine and biology.

[225]  M. Takemura,et al.  L-tryptophan-kynurenine pathway metabolite 3-hydroxyanthranilic acid induces apoptosis in macrophage-derived cells under pathophysiological conditions. , 1999, Advances in experimental medicine and biology.

[226]  W. Banks.  Physiology and pathology of the blood-brain barrier: implications for microbial pathogenesis, drug delivery and neurodegenerative disorders. , 1999, Journal of neurovirology.

[227]  M. Leboyer,et al.  Association between the tryptophan hydroxylase gene and manic-depressive illness. , 1998, Archives of general psychiatry.

[228]  P. Brundin,et al.  Effects of alpha-phenyl-tert-butyl nitrone on neuronal survival and motor function following intrastriatal injections of quinolinate or 3-nitropropionic acid. , 1997, Neuroscience.

[229]  D. Fuchs,et al.  Increase of tryptophan in serum and in cerebrospinal fluid of patients with HIV infection during zidovudine therapy. , 1996, Advances in experimental medicine and biology.

[230]  A. Tolstrup,et al.  Differential regulation of the human, interferon inducible tryptophanyl-tRNA synthetase by various cytokines in cell lines. , 1995, Cytokine.

[231]  B. Brew,et al.  Neurocytotoxity of quinolinic acid in human brain cultures. , 1995, Journal of neurovirology.

[232]  Melinda Fitzgerald,et al.  Immunol. Cell Biol. , 1995 .

[233]  C. Marsden,et al.  Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group. , 1992, Annals of neurology.

[234]  S. Markey,et al.  Progressive slowing of reaction time and increasing cerebrospinal fluid concentrations of quinolinic acid in HIV-infected individuals. , 1992, The Journal of neuropsychiatry and clinical neurosciences.

[235]  R. Price,et al.  Inter-relationships between quinolinic acid, neuroactive kynurenines, neopterin and beta 2-microglobulin in cerebrospinal fluid and serum of HIV-1-infected patients. , 1992, Journal of neuroimmunology.

[236]  A. Horita.  SOME BIOCHEMICAL STUDIES ON PSILOCYBIN AND PSILOCIN , 1992 .

[237]  E. Werner,et al.  Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. , 1990, Journal of acquired immune deficiency syndromes.

[238]  R. Price,et al.  Cerebrospinal fluid beta 2 microglobulin in patients infected with human immunodeficiency virus. , 1989, Neurology.

[239]  O. Hayaishi,et al.  Indoleamine 2,3-dioxygenase. , 1982, Methods in enzymology.

[240]  A. Mangoni.  The "kynurenine shunt" and depression. , 1974, Advances in biochemical psychopharmacology.